Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
|Videos|December 9, 2022
Dr. Jonasch on HIF-2α inhibitors in renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Eric Jonasch, MD, discusses the potential of HIF-2α inhibitors, an emerging class of agents for the treatment of patients with renal cell carcinoma. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5